Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 21, 2005

View Archived Issues

Novel CRTH2 receptor antagonist with acceptable PK profile

TK inhibitors fail to stop tumor growth in vivo

Novel H3 receptor antagonist improves memory retention, learning and attention in rats

Zoledronic acid reported more effective than risedronate in Paget's disease of the bone

Update on the benefits of insulin glulisine in diabetes

Daiichi Suntory Pharma acquired by Daiichi Pharmaceuticals

PharmaMar initiates Aplidin combination clinical program

Aridol lung function test enters phase II clinical evaluation for COPD

Altadyne acquires Stem Cell Therapy International Corp.

Cryptome and University of Virginia expand vascular leak alliance

Durect completes phase II trial of SABER pain relief depot

KB-2115 shows promise in phase Ia trials

Promising phase II data prompts continuation of talabostat combination trial

Viventia Biotech receives FDA approval to begin phase II Proxinium trials

StemCells files IND amendment to begin stem cell therapy in Batten disease

JTT-010: A novel PKCbeta inhibitor with therapeutic benefits in diabetic complications

Intercell advances JEV vaccine to phase III

Photofrin photodynamic therapy finds utility in Barrett's esophagus, esophageal cancer

ViaCell suspends phase I trial of CB-001

Marketing suspension of Hexavac recommended by the EMEA

Tarceva receives E.U. approval for lung cancer

Update on the antidiabetic effects of muraglitazar

Ticilimumab shows a favorable safety profile in advanced melanoma patients

Update on the therapeutic benefits of rotigotine in Parkinson's disease and RLS

New agents for treating obesity disclosed in recent patent literature

Antiinfective agents emerge from pharma R&D

Novel therapeutics for cardiovascular diseases reported

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...